临床IB期皮肤黑色素瘤仅行扩大局部切除的结局
单中心回顾性研究纳入125例临床IB期皮肤黑色素瘤患者,均行扩大局部切除而未行前哨淋巴结活检,中位随访43.2个月。黑色素瘤特异性生存概率13个月为99.1%、62个月为90.8%,无复发生存概率20个月为96.6%、60个月为82.7%。作者认为省略前哨淋巴结活检未对生存结局产生不良影响。
要点
- 临床IB期皮肤黑色素瘤省略前哨淋巴结活检后黑色素瘤特异性生存与无复发生存未显示受损。
- 8.8%出现复发,其中区域淋巴结复发仅1.6%,提示省略活检未损害区域淋巴结控制。
- 该结论来自单中心回顾性数据,需谨慎外推至其他人群。
核心结论
- 本研究数据提示,前哨淋巴结活检未为临床IB期皮肤黑色素瘤提供区域淋巴结控制,省略该检查似乎未对黑色素瘤特异性生存或无复发生存产生不良影响。
研究设计与样本
- 单中心回顾性研究,纳入2015至2025年临床IB期(pT1b/2a、cN0、cM0)皮肤黑色素瘤行扩大局部切除且随访至少6个月的患者,共125例。
- 主要终点为黑色素瘤特异性生存与无复发生存,次要终点为复发模式,生存采用Kaplan-Meier分析估计。
主要发现
- 样本49.6%为男性,中位年龄59岁;按Memorial Sloan Kettering与Melanoma Institute of Australia的NCCN风险阈值,分别有34例(27.2%)和43例(34.4%)超过10%的预测前哨淋巴结阳性风险。
- 原发灶部位为 extremity 62.4%、躯干36%、头颈1.6%,主要组织学亚型为浅表扩散型(75.2%),中位随访43.2个月。
关键数值与推荐
- 黑色素瘤特异性生存概率13个月为99.1%、62个月为90.8%。
- 无复发生存概率20个月为96.6%、60个月为82.7%。
临床怎么用
- 对临床IB期皮肤黑色素瘤,在充分评估预测前哨淋巴结阳性风险后,可考虑与患者讨论省略前哨淋巴结活检的选项。
- 术后仍需按随访计划监测局部、in-transit及远处复发。
局限性
- 单中心回顾性设计,样本量125例,中位随访43.2个月,结论需更长期及多中心数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Standard treatment of IB cutaneous melanoma is wide local excision with sentinel lymph node biopsy. Due to the low positivity rate, cost, complications, and limited management changes associated with positive sentinel lymph node biopsy for clinical stage IB melanoma, we sought to determine if omission of sentinel lymph node biopsy impacted outcomes. METHODS: We performed a single-institution retrospective study including patients with clinical stage IB (pT1b/2a, cN0, and cM0) cutaneous melanoma who underwent wide local excision with at least 6 months of follow-up. Primary end points were melanoma-specific survival and recurrence-free survival, and secondary end points were patterns of recurrence. Survival was estimated with Kaplan-Meier analysis. RESULTS: We identified 125 patients from 2015 to 2025. The sample was 49.6% male, with a median age of 59 years. By the National Cancer Comprehensive Network risk thresholds, 34 (27.2%) and 43 (34.4%) exceeded 10% predicted sentinel lymph node + risk per Memorial Sloan Kettering and Melanoma Institute of Australia, respectively. Primary lesion sites were 62.4% extremity, 36% trunk, and 1.6% head and neck. The predominant histologic subtype was superficial spreading (75.2%). Median follow-up was 43.2 months. Melanoma-specific survival probability was 99.1% at 13 months and 90.8% at 62 months. Eleven recurrences (8.8%) were observed: 2 (1.6%) regional lymph node, 4 (3.2%) distant, and 5 (4.0%) in-transit or local. Recurrence-free survival probability was 96.6% at 20 months and 82.7% at 60 months. CONCLUSIONS: Our data suggest that sentinel lymph node biopsy does not confer regional nodal basin control in clinical stage IB cutaneous melanoma, and its omission does not appear to negatively impact melanoma-specific survival or recurrence-free survival.
引用
- Toliver BC, Kringlen K, Hoshi H, et al. Outcomes in clinical stage IB cutaneous melanoma managed with only wide local excision. Surgery. 2026. PMID: 42786088. doi:10.1016/j.surg.2026.110610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。